Overview

PET and MRI Imaging With Scopolamine at the Muscarinic M1 Receptor

Status:
Not yet recruiting
Trial end date:
2024-10-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the target occupancy (TO) of scopolamine at M1 Muscarinic Receptors in the brain after single I.V. doses of scopolamine, in healthy control subjects, using the radiotracer [11C]EMO (also known as [11C]LSN3172176).
Phase:
Phase 1
Details
Lead Sponsor:
Yale University
Collaborator:
Janssen Scientific Affairs, LLC
Treatments:
Butylscopolammonium Bromide
LSN3172176
Scopolamine